Stay updated on LGX818 and MEK162 With Third Agent in BRAF Melanoma Clinical Trial
Sign up to get notified when there's something new on the LGX818 and MEK162 With Third Agent in BRAF Melanoma Clinical Trial page.

Latest updates to the LGX818 and MEK162 With Third Agent in BRAF Melanoma Clinical Trial page
- Check4 days agoChange DetectedA new revision, v3.3.4, has been added and the previous revision, v3.3.3, removed from the page history.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedAdded Revision: v3.3.3 and removed HHS Vulnerability Disclosure and Revision: v3.3.2 from the page.SummaryDifference0.1%

- Check55 days agoChange DetectedA new revision entry (v3.3.2) was added to the history, replacing the previous v3.2.0; the rest of the History page layout remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check62 days agoChange DetectedRemoved the header notice about funding-related data currency and NIH operating status, which previously directed users to cc.nih.gov and opm.gov. The message was a system-level notification rather than core study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check76 days agoChange DetectedThe new screenshot shows a redesigned header and a slightly adjusted layout of the version history table. No data or version entries appear to have changed.SummaryDifference0.1%

- Check105 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.SummaryDifference10%

Stay in the know with updates to LGX818 and MEK162 With Third Agent in BRAF Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LGX818 and MEK162 With Third Agent in BRAF Melanoma Clinical Trial page.